Source link : https://newshealth.biz/health-news/high-responses-in-second-line-chronic-phase-cml/
TOPLINE: Asciminib, a first-in-class BCR–ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug as a dose-escalated second-line therapy for patients with chronic-phase chronic myeloid leukemia (CML) who had suboptimal responses to earlier therapies. METHODOLOGY: The interim analysis on the single-arm, open-label study, […]
The post High Responses in Second-Line Chronic-Phase CML first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-16 19:41:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8